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Description 
 
 
Cannabis is a genus of flowering plant that includes one or more species. 
The plant is believed to be indigenous to Central Asia, China, and the north-
west Himalayas. The common name for Cannabis is hemp, although this 
term is sometimes used to refer only to strains cultivated for "industrial" 
(non-drug) use. Cannabis plants produce a unique family of compounds 
called cannabinoids, several of which produce psychical and/or 
physiological effects when consumed. The crude drug usually comes in the 
form of dried flowers and leaves, resin (hashish), or various extracts. The 
cultivation or possession of Cannabis for drug purposes is outlawed in most 
countries. 
 
 
 
 
 
Figure 1 
 
 
 
 
Cannabis is an annual, flowering herb. The leaves are palmately compound, 
with serrate leaflets. The first pair of leaves usually have a single leaflet, the 
number gradually increasing up to a maximum of about thirteen leaflets per 
leaf (usually seven or nine), depending on variety and growing conditions. 
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At the top of a flowering plant, this number again diminishes to a single 
leaflet per leaf. The lower leaf pairs usually occur in an opposite leaf 
arrangement and the upper leaf pairs in an alternate arrangement on the 
main stem of a mature plant. 
 
 
 
 
 
 
 
Figure 2. Leaf of a Cannabis plant 
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Taxonomy 
 
 
The genus Cannabis was formerly placed in the Nettle (Urticaceae) or 
Mulberry (Moraceae) family, but is now considered along with hops 
(Humulus sp.) to belong to the Hemp family (Cannabaceae). Various types 
of Cannabis have been described, and classified as species, subspecies, or 
varieties: 
- plants cultivated for fiber and seed production, described as low-
intoxicant, non-drug, o fiber types; 
- plants cultivated for drug production, described as high-intoxicant or drug 
types; 
- escaped or wild forms of either of the above types. 
Cannabis plants produce a unique family of terpeno-phenolic compounds 
called cannabinoids, which produce the "high" one experiences from 
smoking marijuana. The two cannabinoids usually produced in greatest 
abundance are cannabidiol (CBD) and/or ∆9-tetrahydrocannabinol (THC), 
but only THC is psychoactive. 
 
 
 
 
 
Figure 3 
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Since the early 1970's, Cannabis plants have been categorized by their 
chemical phenotype or "chemotype," based on the overall amount of THC 
produced, and on the ratio of THC to CBD. Although overall cannabinoid 
production is influenced by environmental factors, the THC/CBD ratio is 
genetically determined and remains fixed throughout the life of a plant. 
Non-drug plants produce relatively low levels of THC and high levels of 
CBD, while drug plants produce high levels of THC and low levels of 
CBD. When plants of these two chemotypes cross-pollinate, the plants in 
the first filial (F1) generation have an intermediate chemotype and produce 
similar amounts of CBD and THC. Female plants of this chemotype may 
produce enough THC to be utilized for drug production. 
 
 
Figure 4. Top of Cannabis plant in vegetative growth stage 
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Popular usage 
 
The National Institute of Drug Abuse defines drug abuse as the non-medical 
use of a substance for psychic effect, dependence, or suicide attempt. 
Marijuana (also known as ganja) and hashish are psychoactive products of 
the plant Cannabis sativa L. subsp. indica (C. indica Lam.). The herbal 
form of the drug consists of dried mature inflorescences and subtending 
leaves of pistillate ("female") plants. The resinous form consists primarily 
of glandular trichomes collected from the same plant material. It has been 
reported that commercial hashish is often no more potent than high quality 
seedless marijuana.1 
However, carefully produced and screened hashish is up to three times as 
potent as the highest quality herb.2 The major biologically active chemical 
compound in Cannabis is THC. It has psychoactive and physiological 
effects when consumed, usually by smoking or ingestion. The minimum 
amount of THC required to have a perceptible psychoactive effect is about 
5 mg. A related compound, ∆9-tetrahydrocannabidivarin, also know as 
THCV, is produced in appreciable amounts by certain drug strains. This 
cannabinoid has been described in the popular literature as having shorter-
acting, flashier effects than THC, but recent studies suggest that it may 
actually inhibit the effects of THC. Relatively high levels of THCV are 
common in African dagga (marijuana), and in hashish from the northwest 
Himalaya. 
The nature and intensity of the immediate effects of cannabis consumption 
vary according to the dose, the species or hybridization of the source plant, 
the method of consumption, the user's psychical and physical characteristics 
(such as possible tolerance), and the environment of consumption. This is 
sometimes referred to as set and setting. Smoking the same cannabis either 
in a different frame of mind (set) or in a different location (setting) can alter 
the effects or perception of the effects by the individual. What the user does 
under the influence can also affect the effects of cannabis. For example, if 
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the user does nothing they will feel relaxed and sleepy, whereas if they 
engage in intense physical or psychical activity they will feel energised. 
Effects of cannabis consumption may be loosely classified as cognitive and 
physical. Anecdotal evidence suggests that drug varieties of Cannabis 
sativa subsp. sativa tend to produce more of the cognitive or perceptual 
effects, while C. sativa subsp. indica tends to produce more of the physical 
effects. 
 
 
Figure 5. A typical utensil use for smoking marijuana. 
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ECS (endocannabinoid system) 
 
The endocannabinoid system includes cannabinoid receptors, their 
endogenous ligands, anandamide and 2-arachidonoyl glycerol, the 
anandamide transporter protein, and two enzimes, fatty acid amide 
hydrolase (FAAH) and monoglyceride lipase (MGL).3 
 
 
 
 
Figure 6 
 
 
 
Cannabinoid receptors 
 
 
Cannabinoid receptor types are denoted by the abbreviation CB and 
numbered in the order of their discovery by a subscript. At present, two 
cannabinoid receptor types have been unequivocally identified, named CB1 
and CB2. These receptors belong to the super family of G-protein-coupled 
transmembrane receptors (GCPR) which are mainly expressed in the central 
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nervous system; especially in the hypothalamus, pituitary gland and in the 
mesolimbic dopamine circuits. It has detected not only in neurones but also 
in astrocytes and microglial cells. 
It is also found in a variety of peripheral tissues such as adipose tissue, 
liver, muscle, the gastrointestinal tract, pancreas, urinary bladder, lung, 
adrenal gland, testis, ovary, prostate and in rat adipose tissue. 
The CB2 receptors is limited essentially to the cells associated with the 
immune system, like spleen, thymus, tonsils, B cells and natural killer cells, 
monocytes, neutrophils and T cells.4 Although absent from the CNS in 
normal conditions, CB2 receptors might be induced in brain microglial cells 
in response to different damaging conditions associated with local 
inflammatory events,5 and recent studies using human neutrophils indicate 
that the CB2 receptors may suppress neutrophil migration during 
inflammation. It is also located in retina,6 skin7 and some malignant cells.8 
 
 
Figure 7 
 
The human CB1 and CB2 receptorss exhibit 68% identity within the 
transmembrane regions, 44% identity throughout the whole protein. A new 
putative cannabinoid receptor gene has been recently identified in the 
invertebrate Ciona intestinalis that share 28% sequence identity with the 
human CB1 and 24% sequence identity with the human CB2.9 
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Figure 8 
 
 
 
 
 
 
 
 
 
 
 
     Figure 9 
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Endogenous ligands of cannabinoid receptors 
 
 
The individuation of endogenous ligands for these receptors has been 
yielded after cannabinoid receptors discovery. The endogenous ligand of 
the CB1 receptors is anandamide whereas the endogenous ligand of the 
CB2 is 2-arachidonylglycerol (2-AG) (Figure 10). They are synthesized 
from membrane-derived phospholipids whose biologic effects are mediated 
through coupling with the specific, widely expressed ECS receptors located 
presynaptically.10 The synthesis of anandamide is Ca2+-dependent and is 
produced locally by the phospholipase D-mediated cleavage of the 
membrane precursor called N-arachidonoyl-phosphatidylethanolamine 
(NArPE). While the synthesis of 2-arachidonylglycerol is produced by the 
diacylglycerols (DAG) lipase cleavage of the membrane precursor. Because 
endocannabinoids are lipophilic compounds derived from membrane 
phospholipids, they do not need to be stored in synaptic vesicles like other 
neurotransmitters.11 In the brain, they are produced by neurons at their sites 
of action and act on demand, generating a transient, rapid effect before 
being hydrolyzed and inactivated by fatty acid amide hydrolase (FAAH), 
which breaks the amide bond and releases arachidonic acid and 
ethanolamine.10, 11 Because of their lipophilic nature and the mechanism of 
their synthesis and release, endocannabinoids are considered as local 
neuromodulators.12 
 
 
 
Figure 10 
15 
 
  Signal transduction activated by cannabinoid 
receptors 
 
The protein G, which is coupled to receptor, is constituted by the α and βγ 
subunits and the G protein (Gi/Go) associated to cannabinoid receptors is 
sensible to pertussis toxin. The affinity of CB1 and CB2 for Gi or Go 
proteins may be different as revealed by several studies on cannabinoid 
ligand binding or regulation of [35s] GTPγS binding. Whereas, activation 
of both of them display a high affinity for Gi, agonist stimulation of CB1 
also result in a high-affinity saturable interaction with Go but CB2 receptors 
do not interact efficiently with Go. It has been reported that the affinity of 
CB1 receptors for Go is ten fold higher than that of the CB2.13 It has been 
described that the juxtamembrane C-terminal region of CB1 receptorss 
(amino acids 401-417) and the second and third intracellular loops are 
critical for Gi/o protein coupling and that the distal C-terminal tail domain 
profoundly modulates both the magnitude and kinetics of signal 
transduction.14 In the CB2 receptors it has been described the existence of 
two cysteins, C313 and C320, that are located in this C-terminal region, that 
may play important roles for receptor-G protein coupling and receptor 
desensitization. Also, the third transmembrane domain in the CB2, 
particularly the Asp-Arg-Tyr motif, may be crucial for interacting with G 
proteins.  
Some effects are independent by interaction with G proteins, these are 
negative regulation of adenylate cyclase and the cAMP/protein kinase A 
(PKA)-dependent pathway. An effect mediated by G protein is inhibition of 
calcium channels. In fact cannabinoid agonists reduce the amplitude of 
voltage-gated calcium currents in neuronal cells through Gi/o proteins. 
Cannabinoids also modulate K+ channels and cannabinoids as THC cause a 
depression of inward sodium current determining a depression of action 
potentials.15, 16 CB2 receptors seems to be independent of channel 
activation. 
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These GPCRs (G protein-coupled receptors) can stimulate the mitogen-
activated protein kinase (MAPK) cascade and induce cellular proliferation. 
The mammalian MAPK family consists of three subfamilies with multiple 
members: the extracellular signal-regulated kinases (ERK), the Jun amino-
terminal kinases/stress-activated kinases (JNK/SAPK), and the p38 
MAPKs. While ERK is involved in regulation of cell division and growth, 
the other two subfamilies are activated by stress signals and inflammatory 
cytokines and have been related with cellular death and immune disorders. 
In addition, the activation of CB2 receptorss has been also linked to the 
stimulation of additional intracellular pathways including the 
phosphatidylinositol 3-kinase (PI3K)/Akt pathway, which has been 
associated with pro-survival effects, and the de-novo synthesis of the 
sphingolipid messenger ceramide, which has been linked with the pro-
apoptotic effects of cannabinoids (Figure 11-12). 
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Role of cannabinoids 
 
 
 
 
 
Signal transduction activated by CB1 receptors. 
 
Figure 11 
 
 
  Signal transduction activated by CB2 receptors. 
 
Figure 12 
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Role of cannabinoids 
 
For over 4000 years, Cannabis sativa L extract have been widely used as 
recreational drug and as therapy for a variety of disorders. The discovery of 
psychoactive principle of Cannabis sativa, ∆9-tetrahydrocannabinol 
initiated research into the physiological role of cannabinoids. In the last 
years our understanding has been modified significantly by new discovery. 
Cannabinoids are best known for their effects on CNS functions. They 
produce euphoria, alterations in cognition and analgesia, have 
anticonvulsant properties and affect temperature regulation, sleep and 
appetite. However, cannabinoids also possess immunomodulatory activity 
and anti-inflammatory properties. Many diseases of the CNS involve 
inflammation, and cause an up regulation of cytochines and other 
inflammatory mediators in the CNS. Alzheimer’s disease (AD), Parkinson’s 
disease (PD) and amyotrophic lateral sclerosis (ALS) are among the best 
examples of neurodegenerative disorders of the CNS associated with 
intense inflammation, whereas multiple sclerosis (MS) and HIV-associated 
dementia are inflammatory disorders of the CNS that lead to diffuse 
neuronal damage. 
Therefore cannabinoids may be potential therapeutic agents in neurological 
diseases. Recent studies revealed mainly role of cannabinoids in: 
- Cognition: the most prominent among the various consequences of CB1 
receptors activation by exogenous agonist are disruptive effects on working 
memory, i.e. on processes necessary to learn and react to new information 
that differs from session to session. 
- Emotionally: blockade of CB1 receptorss by SR141716A (CB1 agonist) 
caused an increase in anxietyrelated behavior.17, 18, 19 In contrast, lower 
doses of SR141716A had no effects.20 Data obtained in mice were more 
inconsistent. Administration of SR141716A either decreased21 or increased 
anxiety-related behaviour, depending on the genetic background of animals 
and the test situation. 
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- Multiple sclerosis (MS): is the most important chronic inflammatory 
demyelinanting disorder of the CNS. The cannabis and cannabinoid 
agonists may be effective in ameliorating symptomatology of MS, 
especially spasticity and pain. The benefits of cannabinoids agonist the 
symptomatology associated with chronic inflammatory demyelinanting 
pathologies, may be exert at multiple levels: by improving motor function, 
by limiting neuroinflammation, by promoting remyelination. 
- Immune modulation: the cannabinoid CB2 receptors is expressed 
abundantly in various types of inflammatory cells in particular in B cells. 
The CB2 receptorss has been associated with most of immunomodulatory 
activity of cannabinoids, but also CB1 may be linked to cannabinoid-
mediated alterations of immune cell reactivity. Cannabinoids exhibit 
immunosopressive properties. 
- Appetite and energy regulation: the CBr is postulated to connect the 
physical and emotional responses to stress with appetite and energy 
regulation (general stress-recovery system). Stimulation of the CBr may 
possibly occur as a consequence of obesity, leading to increased levels of 
endocannabinoids, which disrupt the feedback mechanism involved in 
energy balance. The CBr affects energy balance, glucose homeostasis, and 
lipogenesis because of the cannabinoids receptors are located in the adipose 
tissue, the liver, the pancreas and the skeletal muscle. 
- Obesity: activation of the CBr increases food intake and promotes weight 
gain. The blockade of the CB1 receptors reduces body weight in animals 
through central and peripheral action. 
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Pharmacological role of cannabinoi receptors 
 
The physiological and therapeutic potential of the CB2 receptors largely 
remains unexplored; however, recent data indicate that CB2 cannabinoid 
receptors participate in the control of peripheral pain, inflammation, 
osteoporosis, growth of malignant gliomas, tumors of immune origin, and 
immunogical disorders such as multiple sclerosis. The activation of the 
cannabinoid signaling system, in discrete brain regions after pathological 
neuroinflammatory insults, represents an endogenous response of the brain 
to maintain nerve cell homeostasis and to reduce the injury associated with 
conditions of excitotoxicity, inflammation, trauma, infection and other 
types of neurotoxic stimuli.  
 
Pain 
 
The use of cannabis has been described in classical and recent literature for 
the treatment of pain, but the potential for psychotropic effects as a result of 
the activation of central CB1 receptorss places a limitation upon its use; 
there are, however, a number of modern approaches being undertaken to 
circumvent this problem. Selective CB2 agonists and peripherally restricted 
CB1 or CB1/CB2 dual agonists are being developed for the treatment of 
inflammatory and neuropathic pain, as they demonstrate efficacy in a range 
of pain models. CB2 receptorss were originally described as being restricted 
to cells of immune origin, but there is evidence for their expression in 
human primary sensory neurons, and increased levels of CB2 receptorss 
reported in human peripheral nerves have been seen after injury,  
particularly in painful neuromas.  
CB2 receptors agonists produce antinociceptive effects in models of 
inflammatory and nociceptive pain, and in some cases these effects involve 
activation of the opioid system. In addition, CB receptor agonists enhance 
the effect of µ-opioid receptor agonists in a variety of models of analgesia, 
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and combinations of cannabinoids and opioids may produce synergistic 
effects. Antinociceptive effects of compounds blocking the metabolism of 
anandamide have been reported, particularly in models of inflammatory 
pain. There is also evidence that such compounds increase the analgesic 
effect of non steroidal anti-inflammatory drugs (NSAIDs), raising the 
possibility that a combination of suitable agents could, by reducing the 
NSAID dose needed, provide an efficacious treatment strategy, while 
minimizing the potential for NSAID-induced gastrointestinal and 
cardiovascular disturbances. Other potential “partners” for endocannabinoid 
modulatory agents include α2-adrenoceptor modulators, peroxisome 
proliferatoractivated receptor α agonists and TRPV1 antagonists. An 
extension of the polypharmacological approach is to combine the desire 
pharmacological properties of the treatment within a single molecule. 
Hopefully, these approaches will yield novel analgesics that do not produce 
the psychotropic effects that limit the medicinal use of cannabis.22 
It has been well established that the ability of cannabinoids to affect pain 
perception has supra-spinal, spinal and peripheral components.23 With 
respect to the peripheral component, local administration of both synthetic 
cannabinoids and exogenous anandamide and 2-AG produce 
antinociceptive effects in the formalin model of inflammatory pain.24 
Fride et al. (2004)25 have identified analog s of the (+)-enantiomer of 
cannabidiol that are active towards CB receptors and reduce the pain 
response in the formalin model of inflammatory pain, without producing 
overt signs of central CB1 receptors activation. Other peripherally restricted 
CB1 or CB1/CB2 receptors agonists are currently being investigated as 
potential approaches to the treatment of pain. A good example of this is the 
study of  Dziadulewicz et al. (2007)26. These authors reported that 
naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone bound as an 
agonist to human CB1 and CB2 receptorss with IC50 values of 15 and 98 
nM, respectively, and produced a good separation of effects upon 
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neuropathic pain and catalepsy, consistent with a limited penetration of the 
compound into the brain. 
 
Inflammation 
 
  Activation of cannabinoid CB1 and CB2 receptors subtypes suppresses pain 
behaviour resulting from tissue injury and inflammation. The ability of 
peripheral cannabinoid mechanisms to modulate the development of 
inflammatory nociception is well established, less is known about 
peripheral cannabinoid antihyperalgesic mechanisms after the establishment 
of chronic inflammation. Local administration of agonist suppressed tactile 
allodynia and mechanical hyperalgesia with the expected pharmacological 
specificity. However, antihyperalgesia efficacy and pharmacological 
specificity for the CB2 selective agonist was less robust in tests of thermal 
compared to mechanical hypersensitivity. Local administration of 
cannabinoids suppress capsaicin-evoked calcitonin gene-related peptide 
release in rat spinal cord in vitro,27 suggesting a possible neuronal 
mechanism of action. CB2 receptors protein has been identified in 
microglial cultures of neonatal rat spinal cord,27 suggesting the existence of 
additional non-neuronal substrates capable of mediating the 
antihyperalgesic actions. Activation of CB2 receptors on skin keratinocytes 
stimulates production of β-endorphin to induce antinociception through 
activation of µ-opioid receptor.28 Locally administered CB1 and CB2 
selective agonists (respectively ACEA and AM 1241) induced qualitatively 
similar suppressions of allodyna and hyperalgesia. Local administration of 
either ACEA and AM1241 at site of inflammation may suppress 
antihyperalgesic efficacy by reducing primary afferent sensitization, effects 
consistent with the observation that cannabinoids suppress capsaicin-
evoked calcitonin gene-relatedpeptide release.27,29 Carrageenan also 
enhances C-fibre-mediated responses and windup in spinal dorsal horn 
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neurons effects, that enhance spinal neuronal excitability. These effects are 
also modulated by both CB1 30 and CB2 specific mechanisms.31       
 
 Table 1. The pharmacology of some of the CB1/CB2  selective compounds. 
 
 
 
Neuroprotection 
 
Recent studies have now implicated CB2 receptorss in neuroprotective 
activity of cannabinoids by blocking of microglia activation (Figure 13), 
mainly through a series of glia-dependent anti-inflammatory actions.32 
Microglia have an active role in the defensive attack against viruses and 
bacteria, but intense microglial activation, such as that produced to clear up 
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apoptotic cells or neuron debris during neurodegenerative disorders, can be 
detrimental to the survival of neighboring cells. Substantial in vivo and in 
vitro results show that cannabinoid protect neurons from death.32, 33, 34 This 
neuroprotection might be relevant for the treatment of both acute brain 
injury (e.g. cerebral ischemia and trauma) and chronic neurodegenerative 
disorders (e.g. Alzheimer’s disease, Parkinson’s disease, Huntington’s 
disease, amyotrophic lateral sclerosis and multiple sclerosis). 
 
 
 
Figure 13 
 
 
Amyotrophic lateral sclerosis (ASL): is a neurodegenerative disease 
characterized by rapid progressive degeneration of motor neurons in the 
brain and spinal cord, paralysis and death within 2-5 years from the 
diagnosis. ASL is the third most common neurodegenerative cause of adult 
death, after Alzheimer’ s disease and Parkinson’s disease.  Most cases of 
ASL are sporadic and are probably acquired, while approximately 10% are 
familial. Despite a variety of putative underlying oxidative stress, 
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neuroinflammation, autoimmunity, a defect in neuronal glutamate transport, 
glutamate toxicity and mutations of superoxide dismutase gene. Recent 
evidence indicates that ASL is a disease characterized by chronic 
inflammation.35, 36 Microglia are the resident macrophages of CNS and in 
response to CNS injury microglia quickly convert to on “active” state 
during which they change to on amoeboid shape, up-regulate the cell-
surface expression of a variety of surface antigens and secrete several pro-
inflammatory molecules37 including interleukin-1β, tumour necrosis factor-
α, nitric oxide,37 oxygen radical, glutamate, proteases and contribute to the 
pathogenesis of neurologic disorders. The microglial activation in the CNS 
suggest a primary neuroinflammatory state with deleterious effects on 
surrounding neurons.38 Recent study reported elevated levels of CB2 
receptorss in microglia isolated from post-mortem human spinal cord of 
ASL patients39 moreover recently in vitro studies demonstrate that CB2 
receptorss are up-regulated in microglia in response to inflammatory 
stimuli40 and that CB2 agonist suppress microglial activation.41 In 2005 
Jared Ehrart et al showed that the CB2 agonist JWH 015 inhibits INF-γ- 
induced microglial CD40 expression. They proved that when CB2 is 
stimulated by the presence of JWH 015 the pro-inflammatory molecules 
were significantly reduced. Recent studies demonstrate that treatment at 
onset with the non selective CB1/CB2 agonist WIN 55-212 produces a 
significant rightward shift in the survival curve on G93A mice reflected by 
an increase of 8.8 days in the survival interval. 
Administration of the selective CB2 agonist AM1241 results in a highly 
significant extension of survival with mice living 56% longer after 
symptom onset than controls. These results suggest that CB2 agonist may 
be effective as pharmacological agents with several distinct advantages for 
the management of this devastating disease.42 
 
Multiple sclerosis (MS): the anti-inflammatory properties of cannabinoids 
against MS pathophysiology seem to be associated with a reduced number 
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of activated microglia in the spinal cord, decreased expression of major 
histocompatibility complex class II, and decreased number of CD4+ T-cells, 
as described in models of MS. Decreased synthesis of proinflammatory 
cytokines are other important effects of these compounds in mice with 
experimental MS. Activation of CB2 receptorss inhibits the production of 
several inflammatory cytokines, cell proliferation and chemiotaxis, down-
regulates macrophage function, inhibits microglial activation and limits 
nitric oxide release (Figure 14). All these factors are critical determinants 
for the maintenance of inflammation in MS. It should be mentioned, 
however, that activated microglia and macrophages express not only CB2 
but also CB1 receptorss, suggesting that both receptor subtypes might be 
important for the anti inflammatory effects of cannabinoids in MS. A report 
also allowed to extend to non-CB1 and non-CB2 receptorss the inhibitory 
action of cannabinoids on astrocyte activation, suggesting a role for these 
receptors in the anti-inflammatory effects of exogenous and endogenous 
cannabinoids in MS and experimental MS. A portion of the 
neurodegenerative damage seen in MS results from the release of toxic 
cytokines and free radicals by activated microglia or other immune cells 
invading the CNS. Thus endocannabinoids, by inhibiting inflammation, also 
exert an indirect neuroprotective action in MS. Cannabinoids, however, 
exert direct neuroprotective effects by limiting glutamate release and 
excitotoxic damage in several neurodegenerative disorders by acting 
through CB1 receptorss. Excitotoxicity plays a crucial role also in MS-
associated neuronal damage, suggesting that pharmacological stimulation of 
CB1 may  contrast neurodegenerative damage also in this disorder.43 
Cannabinoids suppress behavioural responses to noxious stimulation and 
suppress nociceptive transmission through activation of CB2 receptors 
subtype. Indeed, activation of CB2 receptorss on non-neuronal cells has 
been postulated to suppress the release of inflammatory mediators that 
sensitize nociceptors. Thus, non-neuronal substrates as well as neuronal 
substrates may be responsible for the ability of CB2-selective agonists to 
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suppress persistent pain states.44 These mechanisms may also contribute to 
the more pronounced effects of selective CB2 agonists in inflamed 
compared to non-inflamed tissue. 
 
 
Figure 14 
 
 
Glaucoma 
Experimental findings indicate that the cannabinoids (CBs) could be use for 
treatment of glaucoma, because  endocannabinoid system contributes to the 
control of intraocular pressure (IOP), by modulating both production and 
drainage of aqueous humor. There is also a growing body of evidence of the 
involvement of this system in mechanisms leading to the death of retinal 
ganglion cells, which is the end result of glaucoma. 
Glaucoma is an optic neuropathy characterized by apoptotic death of the 
retinal ganglion cells (RGCs) and loss of the axons that make up the optic 
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nerve.45 The changes provoked by glaucoma are progressive, and if left 
untreated can produce severe visual-field deficits. 
The pathogenesis of glaucoma is complex and multifactorial, but elevated 
intraocular pressure (IOP) is one of the risk factors most closely associated 
with both onset and progression of the disease. Increases in the IOP are 
believed to be responsible for blood-flow alterations that ultimately lead to 
hypoxia and ischemia of the retina and the optic nerve. Treatment — 
medical or surgical — is aimed at reducing IOP to prevent structural and 
functional damage, but this approach is not always sufficient to block 
progression of the disease and to prevent blindness.46 Progressive optic 
nerve damage has in fact been documented in many glaucoma patients, 
whose IOP has been pharmacologically or surgically normalized,47 and in 
others whose untreated pressure is well within the normal range (normal 
tension glaucoma).48 Therefore, it seems clear that the damage caused by 
glaucoma is related in part to other factors (vascular, genetic, etc.) that have 
yet to be identified. Experimental data suggest that the excitotoxic cascade 
triggered by glutamate plays a fundamental role in RGC damage associated 
with glaucoma.49 Elevated intravitreal levels of this neurotransmitter have 
been documented in experimental models of glaucoma50  and in glaucoma 
patients.51 
A great deal of information concerned with the interplay between the 
glutamanergic and endocannabinoid system have been recently 
accumulated in the normal and pathological eye and these open new lanes 
of investigation. 
 Earlier studies demonstrated that CB1 receptors are located in the eye52 and 
that functional CB2 receptors are also expressed in the retina and trabecular 
meshwork.53 
The discovery by Straiker et al. (1999)54 of CB receptors and their agonists 
at the ocular level sparked numerous attempts to determine whether and 
how this system might be involved in physiologic andor pathologic 
processes of the eye. There is a large body of experimental data showing 
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that certain endocannabinoids and synthetic CBs can reduce IOP, and these 
findings have led to the suggestion that CBs might be used in the treatment 
of glaucoma, together with or instead of traditional antiglaucoma drugs (α2-
agonists, carbonic anhydrase inhibitors, prostaglandin analogs, β-
blockers)55. Additional support for the use of this approach has emerged 
from more recent studies, which indicate that the (endo)cannabinoids are 
also capable of producing specific neuroprotective effects at the level of the 
retina. 
The first studies on the IOP-reducing effects of CBs date back to the 1970s. 
Hepler and Frank (1971)56 found that eating or smoking marijuana reduced 
IOP by 5–45% (mean, approximately 25%). However, since the effect 
lasted for only 3–4 h, patients would have to use cannabis 8–9 times a day 
to keep their IOP under control. The beneficial effects of marijuana on 
ocular hypertension were also accompanied by several toxic effects, 
including orthostatic hypotension, increased heart rate, emphysema-like 
lung changes, diverse alterations of the mental state (euphoria, reduced 
attention, short-term memory deficits, and altered motor coordination), and 
at the ocular level they included conjunctival hyperemia associated with a 
50% reduction in tear secretion.57 
Porcella et al. (2001)58 reported that WIN-55-212-2, a synthetic CB that 
binds CB1 and CB2 receptors, decreases IOP in patients with a type of 
glaucoma that was refractory to conventional treatment. Endocannabinoids 
like AEA59 or noladin ether60 have also been found to reduce IOP without 
producing systemic toxic effects. 
In a recent pilot study, sublingual administration of THC reduced IOP in 
patients with glaucoma, without producing any significant systemic side 
effects.61 It seems clear that, while the use of marijuana for the treatment of 
glaucoma is not supported by scientific evidence, other molecules — 
natural and synthetic — that interact with the ocular endocannabinoid 
system are offering new perspectives for the control of IOP. In addition, 
Lograno and Romano (2004)62 showed that activation of the CB1 receptors 
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by AEA or CP55,940 caused contraction of the ciliary muscle, an event 
known to promote outflow of the aqueous humor through the trabecular 
meshwork. 
Experimental findings support the view that drugs capable of interacting 
with the endocannabinoid system exert specific neuroprotective effects.63 
The neuroprotective effects of endocannabinoids (eCBs) might also be 
related to their ability to modulate inflammatory processes. In glaucoma, 
post-ischemic inflammation is thought to be an important factor in the 
induction of cell death. Experimentally induced glaucoma has been shown 
to be associated with massive activation of astrocytes, Muller cells, and 
microglia that leads to the release of factors that are toxic to the ganglion 
cells, including nitric oxide, glutamate, and tumor necrosis factor.64 
Experimental studies have also shown that stimulation of CB1 and CB2 
receptors modulates activation and migration of microglial cells, and thus 
inhibits the production of inflammatory cytokines and nitric oxide in 
models of CNS disease.65 
The identification of plant derived, endogenous, or synthetic CBs capable 
of interacting with the intraocular endocannabinoid system could open new 
perspectives for the treatment of glaucoma. In addition to their ability to 
control IOP elevations caused by the disease, such agents could also 
produce specific neuroprotective effects at the level of retinal ganglio cells, 
whose loss represents the final event along with disease progression. In 
ophthalmology, the risk of serious systemic side effects could be 
substantially reduced by the use of eye drops containing 
(endo)cannabinoids, although topical application is complicated by the 
markedly low water solubility of these molecules. The recent introduction 
of microemulsions and cyclodextrins as vehicles has considerably increased 
the ability of (endo)cannabinoids to diffuse across the cornea, thus 
enhancing their effects on the IOP.65a 
 
 
